Seelos Therapeutics (NASDAQ:SEEL) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.
Earnings & Valuation
This table compares Seelos Therapeutics and Amneal Pharmaceuticals' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Seelos Therapeutics | $380,000.00 | 1,109.47 | $-51,260,000.00 | N/A | N/A |
| Amneal Pharmaceuticals | $1.63 billion | 0.96 | $-361,920,000.00 | $0.27 | 19.26 |
Seelos Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals.
Volatility and Risk
Seelos Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Insider & Institutional Ownership
9.3% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. 7.6% of Seelos Therapeutics shares are owned by company insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Seelos Therapeutics and Amneal Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Seelos Therapeutics | N/A | -543.45% | -217.32% |
| Amneal Pharmaceuticals | 3.30% | 42.02% | 3.82% |
Analyst Ratings
This is a breakdown of recent recommendations for Seelos Therapeutics and Amneal Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Seelos Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Amneal Pharmaceuticals | 0 | 1 | 5 | 0 | 2.83 |
Seelos Therapeutics currently has a consensus target price of $13.6667, indicating a potential upside of 154.74%. Amneal Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 34.62%. Given Seelos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Seelos Therapeutics is more favorable than Amneal Pharmaceuticals.
Summary
Amneal Pharmaceuticals beats Seelos Therapeutics on 7 of the 12 factors compared between the two stocks.
